Related Experiment Video
Updated: Dec 10, 2025
10:01
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
7.7K
CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge.
Debora de Melo Gagliato1, Antonio C Buzaid1,2, Jose Manuel Perez-Garcia3
1Centro Oncológico Antonio Ermírio de Moraes, Beneficência Portuguesa de São Paulo, 01323001 São Paulo, Brazil.
Cancers
|September 5, 2020
Summary
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) have transformed advanced hormone receptor-positive breast cancer treatment, significantly improving survival and quality of life. This review covers CDK4/6 inhibitors in clinical practice and resistance mechanisms.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Hormone receptor-positive (HR+) breast cancer is a major subtype.
- Advanced HR+ breast cancer treatment has been revolutionized by CDK4/6 inhibitors.
- CDK4/6 inhibitors improve progression-free and overall survival in advanced HR+ breast cancer.
Purpose of the Study:
- To review current knowledge on CDK4/6 inhibitors in advanced HR+ breast cancer.
- To summarize clinical practice guidelines for CDK4/6 inhibitors.
- To explore mechanisms of sensitivity and resistance to CDK4/6 inhibitors.
Main Methods:
- Literature review of clinical trials and research studies.
- Analysis of molecular and clinical data on CDK4/6 inhibitor efficacy.
- Synthesis of information on resistance mechanisms.
Main Results:
- CDK4/6 inhibitors plus endocrine therapy significantly improve survival endpoints.
- These inhibitors also enhance response rates and delay chemotherapy initiation.
- Understanding resistance mechanisms is crucial for optimizing treatment.
Conclusions:
- CDK4/6 inhibitors are a cornerstone in advanced HR+ breast cancer therapy.
- Further research is needed to overcome resistance and personalize treatment.
- This review provides a comprehensive overview for clinicians and researchers.
Related Concept Videos
02:34Inhibition of Cdk Activity
5.4K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
02:57Targeted Cancer Therapies
8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.5K
02:15M-Cdk Drives Transition Into Mitosis
6.1K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.1K
02:38Mitogens and the Cell Cycle
7.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K
02:50Combination Therapies and Personalized Medicine
5.7K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K
02:56Treatment Resistant Cancers
3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K